op 1 bmp7  (Stryker)

Journal: Stem Cells International

Article Title: A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives

doi: 10.1155/2016/7290686

Figure Lengend Snippet: Examples of engineered BMP pathway activators.

Article Snippet: Several osteogenic proteins were then cloned, expressed as recombinant human proteins, and demonstrated to induce bone formation [ ], heralding the potential for clinical applicability in orthopedics, which came to actualization in 2001 when recombinant human (rh) BMP7 (OP-1, Stryker) received a humanitarian device exemption (HDE) from the US FDA “for use as an alternative to autograft in recalcitrant long bone nonunions where use of autograft is unfeasible and alternative treatments have failed” (FDA).

Techniques: Modification, Activity Assay, Mutagenesis, Variant Assay, Produced, Binding Assay, Inhibition

Journal: Stem Cells International

Article Title: A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives

doi: 10.1155/2016/7290686

Figure Lengend Snippet: Examples of microRNAs targeting BMP pathway components and their inhibition via anti-miR RNA interference.

Article Snippet: Several osteogenic proteins were then cloned, expressed as recombinant human proteins, and demonstrated to induce bone formation [ ], heralding the potential for clinical applicability in orthopedics, which came to actualization in 2001 when recombinant human (rh) BMP7 (OP-1, Stryker) received a humanitarian device exemption (HDE) from the US FDA “for use as an alternative to autograft in recalcitrant long bone nonunions where use of autograft is unfeasible and alternative treatments have failed” (FDA).

Techniques: Inhibition

Journal: Stem Cells International

Article Title: A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives

doi: 10.1155/2016/7290686

Figure Lengend Snippet: Examples of BMP pathway modulation by receptor ECDs or neutralizing antibodies.

Article Snippet: Several osteogenic proteins were then cloned, expressed as recombinant human proteins, and demonstrated to induce bone formation [ ], heralding the potential for clinical applicability in orthopedics, which came to actualization in 2001 when recombinant human (rh) BMP7 (OP-1, Stryker) received a humanitarian device exemption (HDE) from the US FDA “for use as an alternative to autograft in recalcitrant long bone nonunions where use of autograft is unfeasible and alternative treatments have failed” (FDA).

Techniques:

Journal: Drug delivery and translational research

Article Title: Clinical translation of controlled protein delivery systems for tissue engineering

doi:

Figure Lengend Snippet: Clinical trials of BMP2 and BMP7 release for bone tissue engineering.

Article Snippet: CR systems for the release of BMP2 or BMP7 are FDA-approved and available commercially as INFUSE ® bone graft, a BMP2-soaked collagen sponge, from Medtronic (Memphis, TN) [ 40 – 43 ], and OP-1, a BMP7/collagen paste from Stryker Biotech (Hopkinton, MA) [ 44 ].

Techniques: